Health Condition 1: N309- Cystitis, unspecified Health Condition 2: null- Patients presenting with painful bladder syndrome, who are otherwise healthy
Conditions
Interventions
Intervention1: Tadalafil 5 mg: PDE 5 inhibitor, used safely in erectile dysfunction
Control Intervention1: Placebo: Placebo
Sponsors
Dr Gajanan Bhat
Eligibility
Inclusion criteria
Inclusion criteria: All the patients presenting with painful bladder syndrome who give their informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. DM 2. HTN 3. Mental disorders 4. Altered LFT/RFT 5. Patient on treatment for bladder pain syndrome 6. Patients with diagnosis of UTI, Malignancy etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in symptom scores( using O’Laery-Sant IC symptom indices and numeric rating scale (NRS) for pain) and Change in bladder capacity using USG after 3 months of start of the study Timepoint: The change in symptom scores( using O’Laery-Sant IC symptom indices and numeric rating scale (NRS) for pain) and Change in bladder capacity using USG at the biginnning and after 3 months of the start of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Drop out rate due to adverse events or worsening of the symptomsTimepoint: Beginning, every two weeks and end of the study | — |
Countries
India
Contacts
Public ContactDr Gajanan Bhat
TSS Shripad Hegde Kadave Institute of Medical Scinces, sirsi
Outcome results
None listed